{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:27:45Z","timestamp":1786512465715,"version":"build-2736575974"},"reference-count":126,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The therapeutic landscape of urological cancers has undergone a paradigm shift with the advent of immunotherapy. This systematic review synthesizes clinical trials that have established new standards of care, complemented by evidence on immunotherapy-radiotherapy combinations and real-world data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search of PubMed\/MEDLINE and Embase (2010\u20132026) identified phase II\/III trials evaluating ICIs, ADCs, vaccines, or cellular therapies, as well as immunoradiotehrapy, observational studies, and registries reporting real-world outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-three clinical trials met the inclusion criteria: bladder cancer (n=14), kidney cancer (n=21), and prostate cancer (n=18), complemented by immunoradiotherapy trials (n=20), and real-world evidence (n=19). In bladder cancer, perioperative durvalumab and Enfortumab Vedotin (EV) plus pembrolizumab improved outcomes in MIBC, and the EV+pembrolizumab combination became a frontline standard for metastatic disease. Disitamab vedotin plus toripalimab improved outcomes in HER2-expressing tumours, and ctDNA-guided adjuvant atezolizumab introduces precision therapy for molecular residual disease. Emerging immunoradiotherapy combinations showed promising bladder-sparing potential (CR rates 64-88%). In kidney cancer, dual ICI and ICI+TKI combinations demonstrated long-term survival benefits. The RAMPART trial introduced adjuvant durvalumab\u00a0\u00b1\u00a0tremelimumab, while transcriptomic-guided therapy and treatment of rare translocation RCC emerged from 2025\u20132026 trials. In prostate cancer, sipuleucel-T remains the first approved cancer vaccine, while newer trials explored ICIs (durvalumab+tremelimumab) and personalized peptide vaccines. Biomarker-driven approaches emerged across all tumor types, including ctDNA-guided therapy in bladder cancer, KIM 1 in kidney cancer, and PD-L1\/DDR status in prostate cancer. Immunoradiotherapy combinations demonstrated activity in mCRPC (CA184-043, 5-year OS 7.9% vs 2.7%) and oligometastatic RCC (RAPPORT, ORR 63%). Real-world evidence confirmed trial findings while revealing critical gaps in access, the prognostic dominance of performance status, and the potential for radiotherapy-immunotherapy synergy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Immunotherapy has become a cornerstone of urological oncology. Current paradigms include early ICI\/ADC intensification in bladder cancer, ICI-based combinations in renal cell carcinoma, and the gradual integration of vaccines and checkpoint inhibitors in prostate cancer. Real-world evidence and immunoradiotherapy represents an emerging frontier, though optimal fractionation and sequencing require further investigation. Despite major advances, challenges remain in overcoming resistance, optimizing sequencing, and ensuring equitable access.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1871832","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:38:11Z","timestamp":1786509491000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy in urological cancers: new paradigms and a systematic review of clinical trials and real-world evidence"],"prefix":"10.3389","volume":"16","author":[{"given":"Nabil","family":"Ismaili","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health (UM6SS), Mohammed VI Foundation of Sciences and Health (FM6SS)","place":["Casablanca, Morocco"]},{"name":"Oncopathology, Biology and Environment of Cancer Laboratory, Mohammed VI Center for Research and Innovation (CM6RI), Mohammed VI Foundation of Sciences and Health (FM6SS)","place":["Rabat, Morocco"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaa","family":"El Majjaoui","sequence":"additional","affiliation":[{"name":"Oncopathology, Biology and Environment of Cancer Laboratory, Mohammed VI Center for Research and Innovation (CM6RI), Mohammed VI Foundation of Sciences and Health (FM6SS)","place":["Rabat, Morocco"]},{"name":"Department of Radiotherapy, Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health (UM6SS), Mohammed VI Foundation of Sciences and Health (FM6SS)","place":["Casablanca, Morocco"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1780259","article-title":"Redefining standards: a comprehensive systematic review of practice changing advances in GU oncology from ASCO and ESMO 2025","volume":"17","author":"Ismaili","year":"2026","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer--a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.122","article-title":"Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer","volume":"21","author":"Yang","year":"2003","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119132","article-title":"The role of regulatory T cells in the pathogenesis and treatment of prostate cancer","volume":"284","author":"Karpisheh","year":"2021","journal-title":"Life Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2005.08.010","article-title":"Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells","volume":"24","author":"Lin","year":"2006","journal-title":"Urol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.6.10.1031","article-title":"Telomerase-based immunotherapy of cancer","volume":"6","author":"Carpenter","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: driving T cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.copbio.2016.02.001","article-title":"Biomaterials for enhancing anti-cancer immunity","volume":"40","author":"Koshy","year":"2016","journal-title":"Curr Opin Biotechnol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.annonc.2025.09.017","article-title":"ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)","volume":"37","author":"Roupret","year":"2026","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.08.014","article-title":"A novel heterologous prime-boost strategy using RUTI vaccine to improve the Bacillus Calmette-Gu\u00e9rin response in non-muscle-invasive bladder cancer patients: phase 1 RUTIVAC-1 trial","volume":"89","author":"Buisan","year":"2026","journal-title":"Eur Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-472822","article-title":"Advancing perioperative treatment options for localized muscle-invasive bladder cancer: a step forward","volume":"45","author":"Ribal","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012045","article-title":"Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial","volume":"13","author":"Blanc","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.129","article-title":"LBA110 A blinded, exploratory phase II trial of nivolumab and the GDF-15 neutralizing antibody visugromab or placebo as neoadjuvant treatment of patients with muscle-invasive bladder cancer (MIBC): primary results of the GDFather-NEO trial","volume":"36","author":"Necchi","year":"2025","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-4-35","article-title":"Chemotherapy in advanced bladder cancer: current status and future","volume":"4","author":"Ismaili","year":"2011","journal-title":"J Hematol Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.116520","article-title":"Emergence of human epidermal growth factor receptor 2 as a key biomarker and therapeutic target in advanced urothelial carcinoma","volume":"17","author":"Ismaili","year":"2026","journal-title":"World J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4500","article-title":"Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): final results for cisplatin-ineligible patients from the CheckMate 901 trial","volume":"43","author":"Van Der Heijden","year":"2025","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.05.017","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with nonvisceral or lymph node-only disease","volume":"88","author":"Bellmunt","year":"2025","journal-title":"Eur Urol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.04.004","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: long-term analyses of patient-reported outcomes and quality-adjusted time without symptoms or toxicity from the JAVELIN Bladder 100 trial","volume":"8","author":"Grivas","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.011","article-title":"Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial","volume":"37","author":"Powles","year":"2026","journal-title":"Ann Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"S1485","DOI":"10.1016\/j.annonc.2025.08.3685","article-title":"3071MO Disitamab vedotin plustislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: the phase II DISTINCT-I trial","volume":"36","author":"Huang","year":"2025","journal-title":"Ann Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad231","article-title":"Patient-reported outcomes in KEYNOTE-564: adjuvant pembrolizumab versus placebo for renal cell carcinoma","volume":"29","author":"Choueiri","year":"2024","journal-title":"Oncologist"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2025.365","article-title":"Adjuvant pembrolizumab versus placebo for renal cell carcinoma in the East Asian subgroup of the phase 3 KEYNOTE-564 study","volume":"58","author":"Park","year":"2026","journal-title":"Cancer Res Treat"},{"key":"B38","doi-asserted-by":"publisher","first-page":"S1635","DOI":"10.1016\/j.annonc.2025.09.110","article-title":"First results from RAMPART: An international phase III randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL","volume":"36","author":"Larkin","year":"2025","journal-title":"Annals of Oncology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.007","article-title":"Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma","volume":"36","author":"Rini","year":"2025","journal-title":"Ann Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyag041","article-title":"A prospective external validation of the GRade, Age, Nodes and Tumor score in the ECOG-ACRIN EA8143 PROSPER trial","volume":"31","author":"Buti","year":"2026","journal-title":"Oncologist"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.112","article-title":"LBA95 Neoadjuvant immunotherapy in locally advanced clear cell renal cell carcinoma at risk for recurrence or distant metastases: the randomized phase II NESCIO trial","volume":"36","author":"Burgers","year":"2025","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2025.09.006","article-title":"Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial","volume":"37","author":"Motzer","year":"2026","journal-title":"Ann Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005445","article-title":"Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"10","author":"Rini","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102994","article-title":"Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial","volume":"9","author":"Powles","year":"2024","journal-title":"ESMO Open"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013546","article-title":"Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma","volume":"14","author":"Viray","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03867-5","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial","volume":"31","author":"Rini","year":"2025","journal-title":"Nat Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35288","article-title":"Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: post hoc analysis of the CLEAR trial","volume":"156","author":"Gr\u00fcnwald","year":"2025","journal-title":"Int J Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104073","article-title":"Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial","volume":"9","author":"Choueiri","year":"2024","journal-title":"ESMO Open"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.09.004","article-title":"Nivolumab switch maintenance therapy after tyrosine kinase inhibitor induction in metastatic renal cell carcinoma: a randomized clinical trial by the interdisciplinary working group on renal tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)","volume":"84","author":"Gr\u00fcnwald","year":"2023","journal-title":"Eur Urol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4115","article-title":"A randomized phase II study of MEDI0680 in combination with durvalumab versus nivolumab monotherapy in patients with advanced or metastatic clear-cell renal cell carcinoma","volume":"28","author":"Voss","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"S1298","DOI":"10.1016\/j.annonc.2025.08.3207","article-title":"2591O efficacy of cabozantinib and nivolumab in cluster 1\/2 metastatic clear cell renal cell carcinoma: results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker","volume":"36","author":"Haake","year":"2025","journal-title":"Ann Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35962","article-title":"Administration of nivolumab plus ipilimumab: infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)","volume":"131","author":"Menzies","year":"2025","journal-title":"Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.3208","article-title":"Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic renal cell carcinoma (RCC): results from phase III part of a randomized, open-label, active-controlled phase II\/III study (FRUSICA-2)","volume":"36","author":"Ye","year":"2025","journal-title":"Ann Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01840","article-title":"CALYPSO: final results of savolitinib and durvalumab combination in metastatic papillary renal cancer","volume":"44","author":"Jackson-Spence","year":"2026","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa229","article-title":"Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma","volume":"51","author":"Tachibana","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.06.006","article-title":"Adjuvant atezolizumab in patients with sarcomatoid renal cell carcinoma: a prespecified subgroup analysis of IMmotion010","volume":"7","author":"Karam","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1200\/JCO.2025.43.16_suppl.5000","article-title":"Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer","volume":"43","author":"DeWeese","year":"2025","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2022.12.002","article-title":"A phase 2, double-blind, randomized controlled trial of PROSTVAC in prostate cancer patients on active surveillance","volume":"9","author":"Parsons","year":"2023","journal-title":"Eur Urol Focus"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2026.102638","article-title":"Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: a randomized phase I trial","volume":"7","author":"Ager","year":"2026","journal-title":"Cell Rep Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.eururo.2025.07.006","article-title":"Continuous androgen deprivation therapy with or without metastasis-directed therapy for oligometastatic prostate cancer: the multicenter phase 2 randomized EXTEND trial","volume":"88","author":"Sherry","year":"2025","journal-title":"Eur Urol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/oncolo\/oyad058","article-title":"Flutamide with or without PROSTVAC in non-metastatic castration resistant (M0) prostate cancer","volume":"28","author":"Madan","year":"2023","journal-title":"Oncologist"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001556","article-title":"Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer","volume":"9","author":"Madan","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00678","article-title":"Pasritamig, a first-in-class, bispecific T-cell engager targeting human kallikrein 2, in metastatic castration-resistant prostate cancer: a phase I study","volume":"43","author":"Stein","year":"2025","journal-title":"J Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"B70","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/1078-0432.CCR-24-1612","article-title":"Randomized phase II study of durvalumab with or without tremelimumab in patients with metastatic castration-resistant prostate cancer","volume":"31","author":"Winquist","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.01.061","article-title":"Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial","volume":"81","author":"Schellhammer","year":"2013","journal-title":"Urology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0006","article-title":"Survival outcomes of sipuleucel-T phase III studies: impact of control-arm cross-over to salvage immunotherapy","volume":"3","author":"George","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2334","article-title":"Humoral immune response against nontargeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome","volume":"21","author":"GuhaThakurta","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002903","article-title":"IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Pachynski","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.eururo.2015.12.050","article-title":"A phase 2 randomized controlled trial of personalized peptide vaccine immunotherapy with low-dose dexamethasone versus dexamethasone alone in chemotherapy-naive castration-resistant prostate cancer","volume":"70","author":"Yoshimura","year":"2016","journal-title":"Eur Urol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3892\/or.2020.7847","article-title":"A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel","volume":"45","author":"Noguchi","year":"2021","journal-title":"Oncol Rep"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03024-0","article-title":"Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial","volume":"70","author":"Filaci","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.7298","article-title":"Efficacy and safety of autologous dendritic cell-based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: the VIABLE phase 3 randomized clinical trial","volume":"8","author":"Vogelzang","year":"2022","journal-title":"JAMA Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13397","article-title":"Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine","volume":"108","author":"Koga","year":"2017","journal-title":"Cancer Sci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002903","article-title":"IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Pachynski","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur Urol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2025.05.004","article-title":"Combining radiation therapy with immune checkpoint inhibitors for the management of muscle-invasive bladder cancer: a comprehensive systematic review from the Y-ECI ROSC EORTC Group","volume":"15","author":"Achard","year":"2025","journal-title":"Pract Radiat Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00432-025-06245-3","article-title":"Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review","volume":"151","author":"Rosenfeld","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2636","article-title":"Bladder preservation with durvalumab plus tremelimumab and concurrent radiotherapy in patients with localized muscle-invasive bladder cancer (IMMUNOPRESERVE): a phase II Spanish Oncology GenitoUrinary Group trial","volume":"31","author":"Garcia-Del-Muro","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04271-3","article-title":"Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial","volume":"32","author":"Mellema","year":"2026","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.09.011","article-title":"Pembrolizumab with chemoradiation as treatment for muscle-invasive bladder cancer: analysis of safety and efficacy of the PCR-MIB phase 2 clinical trial (ANZUP 1502)","volume":"7","author":"Weickhardt","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2022.12.012","article-title":"Efficacy and safety of pembrolizumab (MK-3475) in combination with chemoradiotherapy versus chemoradiotherapy alone in muscle-invasive bladder cancer: the MK-3475-992\/KEYNOTE-992 trial","volume":"9","author":"Tissot","year":"2023","journal-title":"Eur Urol Focus"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.04.070","article-title":"Dose-limiting urinary toxicity with pembrolizumab combined with weekly hypofractionated radiation therapy in bladder cancer","volume":"101","author":"Tree","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.01.017","article-title":"A phase 1 trial of durvalumab in combination with Bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: the Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER study","volume":"83","author":"Hahn","year":"2023","journal-title":"Eur Urol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2026.102548","article-title":"Radiation and avelumab in cisplatin-ineligible patients with muscle-invasive bladder cancer","volume":"24","author":"Mouw","year":"2026","journal-title":"Clin Genitourin Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006551","article-title":"Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023","volume":"11","author":"Joshi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.11.024","article-title":"Phase II trial of concurrent nivolumab and radiation therapy for muscle-invasive bladder cancer of older or chemotherapy-ineligible patients","volume":"118","author":"Vaishampayan","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.01.009","article-title":"Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma","volume":"75","author":"Sundahl","year":"2019","journal-title":"Eur Urol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.08.011","article-title":"Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the phase 2 ICE-PAC clinical trial","volume":"81","author":"Kwan","year":"2022","journal-title":"Eur Urol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I\/II study","volume":"24","author":"Slovin","year":"2013","journal-title":"Ann Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur Urol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013906","article-title":"Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer","volume":"14","author":"Bryant","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-0254-y","article-title":"Proof-of-principle phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for grade group 5 prostate cancer: safety, feasibility, and exploratory analysis","volume":"24","author":"Yuan","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2018.100116","article-title":"Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer","volume":"19","author":"Twardowski","year":"2019","journal-title":"Cancer Treat Res Commun"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma-the RAPPORT trial","volume":"81","author":"Siva","year":"2022","journal-title":"Eur Urol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.09.016","article-title":"Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study","volume":"81","author":"Masini","year":"2022","journal-title":"Eur Urol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.778459","article-title":"Radiotherapy and high-dose interleukin-2: clinical and immunological results of a proof of principle study in metastatic melanoma and renal cell carcinoma","volume":"12","author":"Bulgarelli","year":"2021","journal-title":"Front Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1186\/s12885-023-11534-6","article-title":"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer","volume":"23","author":"Roussot","year":"2023","journal-title":"BMC Cancer"},{"key":"B105","doi-asserted-by":"publisher","first-page":"19802","DOI":"10.1038\/s41598-024-70182-3","article-title":"Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study","volume":"14","author":"Rizzo","year":"2024","journal-title":"Sci Rep"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2025.100931","article-title":"Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045","volume":"43","author":"Richters","year":"2025","journal-title":"Cancer Treat Res Commun"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2026.100685","article-title":"Real-world comparison of avelumab maintenance versus pembrolizumab at progression after first-line platinum-based chemotherapy in metastatic urothelial cancer","volume":"11","author":"Bosveld","year":"2026","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.09.014","article-title":"Real-world study of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in France: overall results from the noninterventional AVENANCE study and analysis of outcomes by second-line treatment","volume":"8","author":"Barth\u00e9l\u00e9my","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00262-026-04328-9","article-title":"Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)","volume":"75","author":"Mollica","year":"2026","journal-title":"Cancer Immunol Immunother"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03469-5","article-title":"Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study","volume":"72","author":"Santoni","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-211523","article-title":"Real-world study of treatment with pembrolizumab among patients with advanced urothelial tract cancer in Denmark","volume":"7","author":"Omland","year":"2021","journal-title":"Bladder Cancer"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105862","article-title":"Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study","volume":"10","author":"Maiorano","year":"2025","journal-title":"ESMO Open"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31080351","article-title":"Impact of timing of immunotherapy and cytoreductive nephrectomy in metastatic renal cell carcinoma: real-world data on survival outcomes from the CKCis database","volume":"31","author":"Park","year":"2024","journal-title":"Curr Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf240","article-title":"Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma","volume":"30","author":"De Vries-Brilland","year":"2025","journal-title":"Oncologist"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1186\/s12885-025-15264-9","article-title":"Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group","volume":"25","author":"Fern\u00e1ndez-D\u00edaz","year":"2025","journal-title":"BMC Cancer"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1186\/s12885-025-15264-9","article-title":"Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group","volume":"25","author":"Fern\u00e1ndez-D\u00edaz","year":"2025","journal-title":"BMC Cancer"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02085-6","article-title":"Real-world effectiveness of sipuleucel-T on overall survival in men with advanced prostate cancer treated with androgen receptor-targeting agents","volume":"39","author":"Hafron","year":"2022","journal-title":"Adv Ther"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32445","article-title":"Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer","volume":"125","author":"Higano","year":"2019","journal-title":"Cancer"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2026.101241","article-title":"Real-world perioperative systemic treatment patterns and outcomes in patients with urothelial carcinoma undergoing radical surgery","volume":"47","author":"Miyake","year":"2026","journal-title":"Cancer Treat Res Commun"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1162580","article-title":"Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer","volume":"14","author":"Xu","year":"2023","journal-title":"Front Immunol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13014-024-02465-y","article-title":"Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience","volume":"19","author":"Svedman","year":"2024","journal-title":"Radiat Oncol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.mjafi.2023.07.007","article-title":"Real world experience on patterns of usage and toxicity profile of immunotherapy drugs in Indian patients: a prospective observational study","volume":"81","author":"Kaushik","year":"2025","journal-title":"Med J Armed Forces India"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.12.005","article-title":"Treatment patterns and real-world outcomes for locally advanced or metastatic urothelial cancer in the era of immunotherapy","volume":"10","author":"Hassler","year":"2024","journal-title":"Eur Urol Focus"},{"key":"B124","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1847526","article-title":"Rethinking biomarker strategy in gastric cancer immunotherapy: from tumor to host","volume":"17","author":"Ismaili","year":"2026","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1871832\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:38:18Z","timestamp":1786509498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1871832\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":126,"alternative-id":["10.3389\/fonc.2026.1871832"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1871832","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1871832"}}